Long-term effect of intra-striatal glial cell line-derived neurotrophic factor-releasing microspheres in a partial rat model of Parkinson's disease
Abstract
Glial cell line-derived neurotrophic factor (GDNF) offers the possibility to stimulate axonal regeneration of mesencephalic dopaminergic neurons, which are affected in Parkinson's disease. Nevertheless, a safe and efficient GDNF delivery system that may be used in clinical trials is still lacking. In a previous study, we showed that GDNF-releasing microspheres can deliver the neurotrophic factor for 2 months, allowing in a partial rat model of Parkinson's disease a sprouting of the preserved dopaminergic fibers and functional improvement 8 weeks after the treatment. The present study confirms these previous observations and shows that the amphetamine-induced rotation score is still decreased 24 weeks after the end of GDNF delivery. Nevertheless, the improvement was not statistically significant at the latest time point due to the spontaneous reinnervation observed in the model used.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Implantation of GDNF-loaded PLGA-MS in brains of PD animal models achieved regeneration of affected dopaminergic neurons accompanied by functional improvement.
“The regeneration of affected dopaminergic neurons accompanied by functional improvement could be achieved through the implantation of glial cell-derived neurotrophic factor (GDNF)-loaded PLGA-MS in the brains of PD animal models.129”
From Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles (2019) · cites this paper as [129]
GDNF-loaded microsphere increased TH-positive fibers in striatum and substantia nigra, suggesting neuroprotection and neurorestoration activity.
“Apart from this GDNF-loaded microsphere increase in TH-positive fibers in the striatum and substantia nigra, the results suggested neuroprotection and neurorestoration activity.129,130”
From Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles (2019) · cites this paper as [129]
Cites
The rat brain in stereotaxic coordinates
Palkovits, M. (1983) · Neuropeptides · doi:10.1016/0143-4179(83)90049-5 · Cited by 28,959 · see citing works
The Rat Brain in Stereotaxic Coordinates
Paxinos, G., & Watson, C. (1983) · Elsevier eBooks · doi:10.1016/c2009-0-63235-9 · Cited by 28,585 · see citing works
Direct brain infusion of glial cell line–derived neurotrophic factor in Parkinson disease
Gill, S. S., Patel, N. K., Hotton, G. R., O'Sullivan, K., McCarter, R., Bunnage, M., Brooks, D. J., Svendsen, C. N., & Heywood, P. (2003) · Nature Medicine · doi:10.1038/nm850 · Cited by 1,290 · see citing works
Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD
Nutt, J. G., Burchiel, K. J., Comella, C., Jankovic, J. J., Lang, A. E., Laws, E. R., Lozano, A. M., Penn, R. D., Simpson, R. K., Stacy, M. A., et al. (2003) · Neurology · doi:10.1212/wnl.60.1.69 · Cited by 816 · see citing works
Kirik, D., Rosenblad, C., & Björklund, A. (1998) · Experimental Neurology · doi:10.1006/exnr.1998.6848 · Cited by 663 · see citing works
Björklund, A., Rosenblad, C., Winkler, C., & Kirik, D. (1997) · Neurobiology of Disease · doi:10.1006/nbdi.1997.0151 · Cited by 247 · see citing works
Axonal sprouting following lesions of the rat substantia nigra
Finkelstein, D. I., Stanić, D., Parish, C. L., Tomas, D., Dickson, K. A., & Horne, M. K. (2000) · Neuroscience · doi:10.1016/s0306-4522(00)00009-9 · Cited by 201 · see citing works
Batchelor, P. (2002) · Molecular and Cellular Neuroscience · doi:10.1006/mcne.2002.1185 · Cited by 199 · see citing works
Péan, J., Venier‐Julienne, M., Boury, F., Meneï, P., Denizot, B., & Benoît, J. (1998) · Journal of Controlled Release · doi:10.1016/s0168-3659(98)00086-8 · Cited by 166 · see citing works
Self-citationRosenblad, C., Martı́nez-Serrano, A., & Björklund, A. (1997) · Neuroscience · doi:10.1016/s0306-4522(97)00269-8 · Cited by 152 · see citing works
In vivo gene delivery of glial cell line-derived neurotrophic factor for Parkinson's disease
Kordower, J. H. (2003) · Annals of Neurology · doi:10.1002/ana.10485 · Cited by 120 · see citing works
Jollivet, C., Aubert‐Pouëssel, A., Clavreul, A., Venier‐Julienne, M., Remy, S., Montero‐Menei, C. N., Benoît, J., & Meneï, P. (2003) · Biomaterials · doi:10.1016/s0142-9612(03)00601-x · Cited by 103 · see citing works
Self-citationMeneï, P., Péan, J., Nerrière‐Daguin, V., Jollivet, C., Brachet, P., & Benoît, J. (2000) · Experimental Neurology · doi:10.1006/exnr.1999.7253 · Cited by 94 · see citing works
Self-citationPéan, J., Meneï, P., Morel, O., Montero‐Menei, C. N., & Benoît, J. (2000) · Biomaterials · doi:10.1016/s0142-9612(00)00141-1 · Cited by 93 · see citing works
Self-citationTörnqvist, N., Björklund, L., Almqvist, P. M., Wahlberg, L. U., & Strömberg, I. (2000) · Experimental Neurology · doi:10.1006/exnr.2000.7411 · Cited by 54 · see citing works
Differential in Vivo Effects of Neurturin and Glial Cell-Line-Derived Neurotrophic Factor
Hoane, M. R., Gulwadi, A. G., Morrison, S., Hovanesian, G., Lindner, M. D., & Tao, W. (1999) · Experimental Neurology · doi:10.1006/exnr.1999.7175 · Cited by 51 · see citing works
Véziers, J., Lesourd, M., Jollivet, C., Montero‐Menei, C. N., Benoît, J., & Meneï, P. (2001) · Journal of neurosurgery · doi:10.3171/jns.2001.95.3.0489 · Cited by 44 · see citing works
Self-citationCharacterization of a Fibrin Glue-Gdnf Slow-Release Preparation
Cheng, H., Fraidakis, M., Blombäck, B., Lapchak, P. A., Hoffer, B. J., & Olson, L. (1998) · Cell Transplantation · doi:10.1016/s0963-6897(97)00122-x · Cited by 44 · see citing works
Gouhier, C., Chalon, S., Aubert‐Pouëssel, A., Venier‐Julienne, M., Jollivet, C., Benoît, J., & Guilloteau, D. (2002) · Synapse · doi:10.1002/syn.10063 · Cited by 41 · see citing works
Self-citationNakao, N., Yokote, H., Nakai, K., & Itakura, T. (2000) · Journal of neurosurgery · doi:10.3171/jns.2000.92.4.0659 · Cited by 37 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles
Singh, A. P., Biswas, A., Shukla, A., & Maiti, P. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0068-3 · Cited by 645 · see citing works
Effective GDNF brain delivery using microspheres—A promising strategy for Parkinson's disease
Garbayo, E., Montero-Menei, C. N., Ansorena, E., Lanciego, J. L., Aymerich, M. S., & Blanco-Prieto, M. J. (2009) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.12.010 · Cited by 150 · see citing works
Self-citationGéral, C., Angelova, A., & Lesieur, S. (2013) · Pharmaceutics · doi:10.3390/pharmaceutics5010127 · Cited by 124 · see citing works
Cell and biomolecule delivery for tissue repair and regeneration in the central nervous system
Donaghue, I. E., Tam, R. Y., Sefton, M. V., & Shoichet, M. S. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.05.040 · Cited by 101 · see citing works
de Tassigny, X. D., Pascual, A., & López‐Barneo, J. (2015) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2015.00010 · Cited by 99 · see citing works
Lampe, K. J., Kern, D. S., Mahoney, M. J., & Bjugstad, K. B. (2011) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbm.a.33011 · Cited by 98 · see citing works
Therapeutic potential of controlled drug delivery systems in neurodegenerative diseases
Popović, N., & Brundin, P. (2006) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2005.09.040 · Cited by 91 · see citing works
Therapeutic Potential of Neurotrophic Factors in Neurodegenerative Diseases
Levy, Y. S., Gilgun‐Sherki, Y., Melamed, E., & Offen, D. (2005) · BioDrugs · doi:10.2165/00063030-200519020-00003 · Cited by 90 · see citing works
Sajadi, A., Bensadoun, J., Schneider, B. L., Bianco, C. L., & Aebischer, P. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.10.006 · Cited by 79 · see citing works
Glavaski‐Joksimovic, A., Virág, T., Mangatu, T. A., McGrogan, M. P., Wang, X. S., & Bohn, M. C. (2010) · Journal of Neuroscience Research · doi:10.1002/jnr.22435 · Cited by 77 · see citing works
Experimental and Clinical Studies
Sarkar, N. (2005) · Cited by 70 · see citing works
Herrán, E., Ruíz-Ortega, J. Á., Aristieta, A., Igartúa, M., Requejo, C., Lafuente, J. V., Ugedo, L., Pedraz, J. L., & Hernández, R. M. (2013) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2013.03.034 · Cited by 68 · see citing works
Drug delivery into the brain using poly(lactide-co-glycolide) microspheres
Meneï, P., Montero‐Menei, C. N., Venier‐Julienne, M., & Benoît, J. (2005) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2.2.363 · Cited by 57 · see citing works
Self-citationInjectables and Depots to Prolong Drug Action of Proteins and Peptides
Ibeanu, N., Egbu, R., Onyekuru, L., Javaheri, H., Khaw, P. T., Williams, G. R., Brocchini, S., & Awwad, S. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12100999 · Cited by 56 · see citing works
Suzuki, S., Kawamata, J., Matsushita, T., Matsumura, A., Hisahara, S., Takata, K., Kitamura, Y., Kem, W. R., & Shimohama, S. (2012) · Journal of Neuroscience Research · doi:10.1002/jnr.23160 · Cited by 53 · see citing works
Tatard-Leitman, V. M., Sindji, L., Branton, J., Aubert‐Pouëssel, A., Colleau, J., Benoît, J., & Montero‐Menei, C. N. (2007) · Biomaterials · doi:10.1016/j.biomaterials.2006.12.021 · Cited by 52 · see citing works
Self-citationAdvances in Nanomedicine for the Treatment of Alzheimer’s and Parkinson’s Diseases
Hernando, S., Gartziandia, O., Herrán, E., Pedraz, J. L., Igartúa, M., & Hernández, R. M. (2016) · Nanomedicine · doi:10.2217/nnm-2016-0019 · Cited by 48 · see citing works
Nanomedicine and drug delivery: A comprehensive review of applications and challenges
Singh, K., Singhal, S., Pahwa, S., Sethi, V. A., Sharma, S., Singh, P., Kale, R. D., Ali, S. W., & Sagadevan, S. (2024) · Nano-Structures & Nano-Objects · doi:10.1016/j.nanoso.2024.101403 · Cited by 53 · see citing works
Prospects for polymer therapeutics in Parkinson's disease and other neurodegenerative disorders
Newland, B., Newland, H., Werner, C., Rosser, A., & Wang, W. (2015) · Progress in Polymer Science · doi:10.1016/j.progpolymsci.2014.12.002 · Cited by 34 · see citing works
Neurotrophic Factors and Neurodegenerative Diseases
Ruozi, B., Belletti, D., Bondioli, L., Vita, A. D., Forni, F., Vandelli, M. A., & Tosi, G. (2012) · International review of neurobiology · doi:10.1016/b978-0-12-386986-9.00009-0 · Cited by 29 · see citing works
Mesa-Infante, V., Afonso‐Oramas, D., Salas-Hernández, J., Rodríguez-Núñez, J., & Barroso‐Chinea, P. (2021) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2021.103684 · Cited by 29 · see citing works
Brain Drug Delivery Systems for Neurodegenerative Disorders
Garbayo, E., Ansorena, E., & Blanco‐Prieto, M. J. (2012) · Current Pharmaceutical Biotechnology · doi:10.2174/138920112803341761 · Cited by 25 · see citing works
Clavreul, A., Sindji, L., Aubert‐Pouëssel, A., Benoît, J., Meneï, P., & Montero‐Menei, C. N. (2006) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2005.11.006 · Cited by 20 · see citing works
Self-citationPsychotropic and Neurotropic Activity
Vogel, H. G. (2007) · Springer eBooks · doi:10.1007/978-3-540-70995-4_6 · Cited by 20 · see citing works
Requejo, C., Ruíz-Ortega, J. Á., Bengoetxea, H., García-Blanco, A., Herrán, E., Aristieta, A., Igartúa, M., Ugedo, L., Pedraz, J. L., Hernández, R. M., et al. (2015) · Molecular Neurobiology · doi:10.1007/s12035-015-9234-y · Cited by 19 · see citing works
Agbay, A. M., Mohtaram, N. K., & Willerth, S. M. (2014) · Drug Delivery and Translational Research · doi:10.1007/s13346-013-0189-0 · Cited by 19 · see citing works
Transplantation of carotid body cells in the treatment of neurological disorders
Yu, G., Fournier, C. N., Hess, D. C., & Borlongan, C. V. (2005) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2004.09.011 · Cited by 18 · see citing works
Stem Cells, Bioengineering, and 3-D Scaffolds for Nervous System Repair and Regeneration
Sandquist, E. J., Uz, M., Sharma, A. D., Patel, B. B., Mallapragada, S. K., & Sakaguchi, D. S. (2016) · Springer eBooks · doi:10.1007/978-3-319-31433-4_2 · Cited by 12 · see citing works
Xue, M., Zhao, Q., Li, Z., Zhang, Z.-P., Mo, Z.-Y., Chen, S.-J., Xiang, S.-Y., & Zhang, Q. (2015) · Neural Regeneration Research · doi:10.4103/1673-5374.165522 · Cited by 10 · see citing works
Growth Factor Therapy for Parkinson’s Disease: Alternative Delivery Systems
Jarrin, S., Hakami, A., Newland, B., & Dowd, E. (2021) · Journal of Parkinson s Disease · doi:10.3233/jpd-212662 · Cited by 9 · see citing works
De, S., Banerjee, S., Rakshit, P., Banerjee, S., & Kumar, S. K. A. (2024) · Current Diabetes Reviews · doi:10.2174/0115733998291968240429111357 · Cited by 6 · see citing works
Supramolecular nanostructure mimics GDNF trophic effects in vitro on human dopaminergic neurons
Carballo-Molina, O. A., Edelbrock, A. N., Alvarez-Saavedra, M., Álvarez, Z., Fyrner, T., Perez‐Rosello, T., Syrgiannis, Z., Chin, S. M., Takata, N., Strong, M. E., et al. (2025) · npj Regenerative Medicine · doi:10.1038/s41536-025-00424-z · Cited by 5 · see citing works
Nanocarriers to mediate the pathways from diabetes toward Parkinson's disease
De, S., & Kuo, Y. (2024) · Journal of the Taiwan Institute of Chemical Engineers · doi:10.1016/j.jtice.2024.105401 · Cited by 5 · see citing works
Nanotechnology Based Approaches for Neurodegenerative Disorders: Diagnosis and Treatment
Hernando, S., Herrán, E., Pedraz, J. L., Igartúa, M., & Hernández, R. M. (2017) · Springer eBooks · doi:10.1007/978-3-319-57696-1_3 · Cited by 4 · see citing works
Parkinson's Disease: Cell Vulnerability and Disease Progression
de Tassigny, X. D., Pascual, A., & López‐Barneo, J. (2015) · Frontiers research topics · doi:10.3389/978-2-88919-676-0 · Cited by 3 · see citing works
Intranasal delivery of GDNF for the treatment of Parkinson's disease
Migliore, M. M. (2008) · doi:10.17760/d10018463 · Cited by 2 · see citing works
Blandini, F. (2009) · Open Access Journal of Clinical Trials · doi:10.2147/oajct.s4660 · Cited by 1 · see citing works
Regenerative and Repair Strategies for the Central Nervous System
Sakaguchi, D. S. (2016) · Springer eBooks · doi:10.1007/978-3-319-44022-4_47 · Cited by 1 · see citing works
Kallman, M. J. (2015) · Springer eBooks · doi:10.1007/978-3-319-05392-9_32
Piltonen, M. (2012) · Työväentutkimus Vuosikirja
Adult Stem Cell Treatment for Central Nervous System Injury
Mead, B., Logan, A., Berry, M., Leadbeater, W. E., & Scheven, B. A. A. (2014) · Current Tissue Engineering · doi:10.2174/2211542003666141013223828
Micro- et nanotechnologies pour l’administration de médicaments au niveau cérébral
Benoît, J. (2012) · Biologie Aujourd hui · doi:10.1051/jbio/2012026
Controlled Delivery of Therapeutic Proteins to the Injured Spinal Cord
Donaghue, I. E. (2016) · TSpace (University of Toronto)
- Authors
- Jollivet, C., Aubert-Pouessel, A., Clavreul, A., Venier-Julienne, M.-C., Montero-Menei, C. N., Benoit, J.-P., & Menei, P.
- Affiliations
- Inserm (FR)
- ORCID
- Clavreul, Anne
- Venue
- Neuroscience Letters
- Publisher
- Elsevier BV
- Published
- 2004-02
- Volume
- 356
- Issue
- 3
- Pages
- 207-210
- ISSN
- 0304-3940 (ISSN-L)
- OpenAlex
- W1996970388
- Cited by
- 43
- References
- 20
- Citations by year
- 2025: 1 · 2024: 3 · 2021: 2 · 2020: 1 · 2019: 1 · 2017: 1 · 2016: 4 · 2015: 6 · 2014: 3 · 2013: 2 · 2012: 5
- FWCI
- 2.01
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Neuroscience Letters (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Fondation de l'Avenir pour la Recherche Médicale Appliquée
- Fondation pour la Recherche Médicale
- Topics
- Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Nerve injury and regeneration
- Health Sciences › Medicine › Neurology › Neurological disorders and treatments
- Keywords
- glial cell line-derived neurotrophic factor, Parkinson's disease, dopaminergic neuron survival, axon regeneration, neurotrophic factor delivery, amphetamine-induced rotation, long-term treatment outcomes, striatum
- MeSH terms
- Amphetamine, Analysis of Variance, Animals, Behavior, Animal, Cell Count, Corpus Striatum, Disease Models, Animal, Female, Immunohistochemistry, Microspheres, Nerve Growth Factors, Nerve Regeneration, Parkinson Disease, Secondary, Stereotaxic Techniques, Stereotyped Behavior, Time, Time Factors, Tyrosine 3-Monooxygenase, Oxidopamine, Rats, Sprague-Dawley, Glial Cell Line-Derived Neurotrophic Factor, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
